1 to 9 of 59 results

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics


The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Generic risk to GSK's Advair prompts buy recommendation from analysts


Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs


Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

Boehringer Ingelheim's Gilotrif could be leading therapy if it overcomes concerns, says GlobalData


Family-owned German drug major Boehringer Ingelheim could face "significant challenges" over its first-line…

AstraZenecaBoehringer IngelheimEuropeGilotrifIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

AstraZeneca in oncology partnerships with University of Cambridge, Cancer Research UK and Blackfield


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reached agreement with the University of Cambridge…

AstraZenecaBlackfieldBoehringer IngelheimJanssenMerck KGaAolaparibOncologyPharmaceuticalResearch

UK academia-pharma collaboration attracts £14.4 million funding


In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

Strong date from Boehringer Ingelheim and Bristol-Myers/AstraZeneca on diabetes drugs presented at ADA


Continuing the string of positive news on diabetes drug developments at the ongoing 70th Scientific Sessions…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbDiabeteslinagliptinOnglyzaPharmaceuticalResearch

1 to 9 of 59 results

Back to top